Log in

OTCMKTS:ALPMYASTELLAS PHARMA/ADR Stock Price, Forecast & News

$18.42
+0.58 (+3.25 %)
(As of 06/1/2020 04:00 PM ET)
Add
Compare
Today's Range
$18.20
Now: $18.42
$18.43
50-Day Range
$15.52
MA: $16.43
$17.84
52-Week Range
$12.48
Now: $18.42
$18.43
Volume56,892 shs
Average Volume77,667 shs
Market Capitalization$34.79 billion
P/E Ratio19.19
Dividend Yield0.88%
Beta0.77
Astellas Pharma Inc. manufactures, markets, and imports and exports pharmaceutical products worldwide. The company offers XTANDI and Eligard for the treatment of prostate cancer; Betanis/Myrbetriq/BETMIGA for overactive bladder (OAB) treatment; Vesicare forOAB treatment; Harnal/Omnic for functional symptoms associated with benign prostatic hyperplasia; VESOMNI for storage symptoms and voiding symptoms associated with benign prostatic hyperplasia; Prograf and Advagraf/Graceptor/ASTAGRAF XL/Prograf XL, animmunosuppressant; and Funguard/MYCAMINE, a candin-type antifungal agent. It also provides Celecox, an anti-inflammatory agent; Lipitor, a treatment for hypercholesterolemia; Micardis/Micombi/Micamlo, a treatment for hypertension; Symbicort for the treatment for adult bronchial asthma and chronic obstructive pulmonary disease; Bonoteo for the treatment for osteoporosis; Suglat for the treatment of type 2 diabetes; and Repatha for the treatment of hypercholesterolemia. In addition, it offers Lexiscan, a pharmacologic stress agent; Tarceva, a treatment for non-small cell lung cancer; CRESEMBA, a azole antifungal; and Dificlir, a novel treatment for CDI. Additionally, it is developing enzalutamide, gilteritinib, enfortumab vedotin, zolbetuximab, roxadustat, and fezolinetant for oncology indications. The company has a collaboration with Actinium Pharmaceuticals, Inc. to apply Actinium warhead enabling technology platform for generating Actinium radio-conjugates with various Astellas targeting agents; and a research collaboration with NapaJen Pharma, Inc. for the discovery and development of oligonucleotide therapeutics. Astellas Pharma Inc. was founded in 1923 and is headquartered in Tokyo, Japan.
Read More
ASTELLAS PHARMA/ADR logo

Beat the Market (BTM) Rank

Analyst Opinion: 0.0Community Rank: 2.7Dividend Strength: 3.3Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.33 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolOTCMKTS:ALPMY
CUSIPN/A
CIKN/A
Phone813-3244-3000

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$11.97 billion
Cash Flow$1.35 per share
Book Value$5.72 per share

Profitability

Miscellaneous

Employees16,617
Outstanding Shares1,888,820,000
Market Cap$34.79 billion
Next Earnings Date8/4/2020 (Estimated)
OptionableNot Optionable

Receive ALPMY News and Ratings via Email

Sign-up to receive the latest news and ratings for ALPMY and its competitors with MarketBeat's FREE daily newsletter.

ASTELLAS PHARMA/ADR (OTCMKTS:ALPMY) Frequently Asked Questions

How has ASTELLAS PHARMA/ADR's stock been impacted by COVID-19 (Coronavirus)?

ASTELLAS PHARMA/ADR's stock was trading at $15.72 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, ALPMY stock has increased by 17.2% and is now trading at $18.42. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of ASTELLAS PHARMA/ADR?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for ASTELLAS PHARMA/ADR in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for ASTELLAS PHARMA/ADR.

When is ASTELLAS PHARMA/ADR's next earnings date?

ASTELLAS PHARMA/ADR is scheduled to release its next quarterly earnings announcement on Tuesday, August 4th 2020. View our earnings forecast for ASTELLAS PHARMA/ADR.

How were ASTELLAS PHARMA/ADR's earnings last quarter?

ASTELLAS PHARMA/ADR (OTCMKTS:ALPMY) announced its earnings results on Thursday, May, 14th. The company reported $0.03 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.20 by $0.17. The firm had revenue of $2.87 billion for the quarter. View ASTELLAS PHARMA/ADR's earnings history.

When did ASTELLAS PHARMA/ADR's stock split? How did ASTELLAS PHARMA/ADR's stock split work?

ASTELLAS PHARMA/ADR shares split on Wednesday, April 2nd 2014. The 5-4 split was announced on Friday, March 14th 2014. The newly minted shares were distributed to shareholders after the closing bell on Tuesday, April 1st 2014. An investor that had 100 shares of ASTELLAS PHARMA/ADR stock prior to the split would have 125 shares after the split.

Has ASTELLAS PHARMA/ADR been receiving favorable news coverage?

News stories about ALPMY stock have been trending very positive recently, InfoTrie Sentiment reports. InfoTrie identifies negative and positive media coverage by monitoring more than six thousand news and blog sources in real time. The firm ranks coverage of companies on a scale of negative five to five, with scores nearest to five being the most favorable. ASTELLAS PHARMA/ADR earned a daily sentiment score of 3.5 on InfoTrie's scale. They also gave press coverage about the company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an impact on the company's share price in the next few days. View the latest news aboutASTELLAS PHARMA/ADR.

Who are some of ASTELLAS PHARMA/ADR's key competitors?

Who are ASTELLAS PHARMA/ADR's key executives?

ASTELLAS PHARMA/ADR's management team includes the following people:
  • Mr. Kenji Yasukawa Ph.D., Pres, CEO & Director (Age 59)
  • Mr. Chikashi Takeda, CFO & Sr. Corp. Exec.
  • Mr. Fumiaki Sakurai, Chief Admin. Officer, Chief Ethics & Compliance Officer and Sr. Corp. Exec.
  • Ms. Linda Friedman, Gen. Counsel & VP
  • Dr. Sef P. Kurstjens, Chief Medical Officer and Pres of Global Devel. (Age 56)

What is ASTELLAS PHARMA/ADR's stock symbol?

ASTELLAS PHARMA/ADR trades on the OTCMKTS under the ticker symbol "ALPMY."

How do I buy shares of ASTELLAS PHARMA/ADR?

Shares of ALPMY can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is ASTELLAS PHARMA/ADR's stock price today?

One share of ALPMY stock can currently be purchased for approximately $18.42.

How big of a company is ASTELLAS PHARMA/ADR?

ASTELLAS PHARMA/ADR has a market capitalization of $34.79 billion and generates $11.97 billion in revenue each year. The company earns $1.80 billion in net income (profit) each year or $0.96 on an earnings per share basis. ASTELLAS PHARMA/ADR employs 16,617 workers across the globe.

What is ASTELLAS PHARMA/ADR's official website?

The official website for ASTELLAS PHARMA/ADR is www.astellas.com.

How can I contact ASTELLAS PHARMA/ADR?

ASTELLAS PHARMA/ADR's mailing address is 2-5-1 Nihonbashi-Honcho Chuo-Ku, Tokyo M0, 103-8411. The company can be reached via phone at 813-3244-3000.

This page was last updated on 6/2/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.